Vaccination against Zika virus infection using mosquito NeSt1 protein

使用蚊子 NeSt1 蛋白预防寨卡病毒感染的疫苗

基本信息

  • 批准号:
    10081573
  • 负责人:
  • 金额:
    $ 29.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-16 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculating virus-infected saliva into host skin during probing and feeding. This saliva contains over one hundred unique proteins and these proteins have diverse functions, including facilitating blood feed. Some of these proteins are known to enhance infectivity and pathogenesis in Zika and other arboviruses by modulating immune responses, and the development of blocking therapies against them could be a good approach to reduce infectivity and pathogenesis in the host. In addition, focusing on mosquito proteins as vaccine targets can overcome the problems associated with the use of viral antigens as a vaccine targets, due to their high variability. In this proposal, we will develop a novel transmission-blocking vaccine against Zika virus (ZIKV) by targeting A. aegypti bacteria responsive protein 1 (AgBR1) and A. aegypti neutrophil stimulating factor 1 (NeSt1) salivary gland protein. Using a yeast surface display screen, we identified a set of A. aegypti salivary proteins that react with sera from mice repeatedly bitten by A. aegypti mosquitoes. Passive immunization with antiserum against two of these proteins, AgBR1 and NeSt1, resulted in significantly more survival in mice infected with ZIKV by mosquito bite. Simultaneous passive immunization with both antisera demonstrated a synergy resulting in higher survival than expected from the individual treatments. Based on these results, in this proposal we intend to carefully examine the protective effects of blocking the mosquito AgBR1 and NeSt1 proteins in preventing severe mosquito-borne ZIKV infection in mice. We will develop a strategy for actively immunizing mice against both proteins towards the development of a vaccine for use in humans. The success of this approach also offers a functional paradigm for developing vaccines against other flaviviruses and other arthropod- borne pathogens of medical importance.
节肢动物传播的病毒(虫媒病毒)对人类和动物健康构成重大威胁

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michel Ledizet其他文献

Michel Ledizet的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michel Ledizet', 18)}}的其他基金

Vaccination against Zika virus infection using mosquito NeSt1 protein
使用蚊子 NeSt1 蛋白预防寨卡病毒感染的疫苗
  • 批准号:
    10194371
  • 财政年份:
    2020
  • 资助金额:
    $ 29.92万
  • 项目类别:
An antigen-detection assay to diagnose Babesia microti infection
诊断田鼠巴贝斯虫感染的抗原检测方法
  • 批准号:
    10403621
  • 财政年份:
    2018
  • 资助金额:
    $ 29.92万
  • 项目类别:
An antigen-detection assay to diagnose Babesia microti infection
诊断田鼠巴贝斯虫感染的抗原检测方法
  • 批准号:
    10082042
  • 财政年份:
    2018
  • 资助金额:
    $ 29.92万
  • 项目类别:
An antigen-detection assay to diagnose Babesia microti infection
诊断田鼠巴贝斯虫感染的抗原检测方法
  • 批准号:
    10200003
  • 财政年份:
    2018
  • 资助金额:
    $ 29.92万
  • 项目类别:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
使用体内表达抗原诊断早期莱姆疏螺旋体病
  • 批准号:
    8876556
  • 财政年份:
    2014
  • 资助金额:
    $ 29.92万
  • 项目类别:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
使用新鉴定的体内表达抗原的莱姆病疫苗
  • 批准号:
    8455815
  • 财政年份:
    2013
  • 资助金额:
    $ 29.92万
  • 项目类别:
A Lyme disease vaccine using newly identified in-vivo expressed antigens
使用新鉴定的体内表达抗原的莱姆病疫苗
  • 批准号:
    8601286
  • 财政年份:
    2013
  • 资助金额:
    $ 29.92万
  • 项目类别:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
使用体内表达抗原诊断早期莱姆疏螺旋体病
  • 批准号:
    8782201
  • 财政年份:
    2012
  • 资助金额:
    $ 29.92万
  • 项目类别:
Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens
使用体内表达抗原诊断早期莱姆疏螺旋体病
  • 批准号:
    8315248
  • 财政年份:
    2012
  • 资助金额:
    $ 29.92万
  • 项目类别:
A serologic assay to measure successful Lyme borreliosis antibiotic therapy
测量莱姆疏螺旋体病抗生素治疗是否成功的血清学检测
  • 批准号:
    8715103
  • 财政年份:
    2010
  • 资助金额:
    $ 29.92万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 29.92万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了